Share Prices & Company Research

Market News

16 Jul 2019 | 08:55

Clinigen Group expects annual revenues to grow by 'at least' 19% amid boost from acquisitions

Clinigen Group, a pharmaceutical and services company, said it expected annual revenues to grow by 'at least' 19%, driven primarily by acquisitions. For the year ended 30 June 2019, the company said it expected to report an increase of revenues of at least 19% on a reported basis and constant currency basis compared to last year. Gross profit was expected to have increased by at least 30% on a reported basis and 31% on a constant currency basis.

Earnings (EBITDA) growth was expected to have increased ahead of gross profit, in line with the board's expectations whilst earnings per share was expected to have increased by at least 15%. 'The strong growth has been driven primarily by acquisitions with each contributing towards the Group's performance,' the company said. 'Two of the largest acquisitions, CSM and the rights to Proleukin in the US, have exceeded expectations.' 'This performance from acquisitions plus good underlying growth overall has offset pressure on the Group's largest product, Foscavir, from an alternative therapy, and from the UK Specials business within Unlicensed Medicines,' it added.

At 8:55am: (LON:CLIN) Clinigen Group share price was +3.75p at 996.75p

Story provided by
Get in touch today
Join Redmayne Bentley
Talk to us now about opening a new account or transferring your account from another provider
0113 243 6941
Get in touch today
Contact your local office
Contact your local office to find out more
The value of your investments and the income from them may go down as well as up, and you could get back less than you invested.
We use cookies on this site to improve your experience and help us provide you with a better website. An explanation of the cookies we use and their purpose can be found within our Cookie Policy. Your continued use of this site means you consent to the use of cookies.